Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TELA Bio (TELA) Accumulated Expenses (2018 - 2025)

Historic Accumulated Expenses for Bio (TELA) over the last 8 years, with Q3 2025 value amounting to $14.6 million.

  • Bio's Accumulated Expenses rose 156.48% to $14.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.6 million, marking a year-over-year increase of 156.48%. This contributed to the annual value of $13.5 million for FY2024, which is 1208.5% down from last year.
  • Bio's Accumulated Expenses amounted to $14.6 million in Q3 2025, which was up 156.48% from $14.0 million recorded in Q2 2025.
  • In the past 5 years, Bio's Accumulated Expenses ranged from a high of $15.3 million in Q4 2023 and a low of $4.7 million during Q1 2021
  • Moreover, its 5-year median value for Accumulated Expenses was $10.9 million (2022), whereas its average is $10.8 million.
  • Per our database at Business Quant, Bio's Accumulated Expenses soared by 12493.46% in 2021 and then crashed by 1208.5% in 2024.
  • Bio's Accumulated Expenses (Quarter) stood at $8.2 million in 2021, then skyrocketed by 33.18% to $10.9 million in 2022, then skyrocketed by 40.77% to $15.3 million in 2023, then fell by 12.08% to $13.5 million in 2024, then rose by 8.57% to $14.6 million in 2025.
  • Its Accumulated Expenses stands at $14.6 million for Q3 2025, versus $14.0 million for Q2 2025 and $12.5 million for Q1 2025.